-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPS-2071 in Irritable Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPS-2071 in Irritable Bowel Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPS-2071 in Irritable Bowel Syndrome Drug Details: OPS-2071 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KGYY-15 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KGYY-15 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KGYY-15 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OP-101 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OP-101 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Livmoniplimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Livmoniplimab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Livmoniplimab in Non-Small Cell Lung Cancer Drug Details: Livmoniplimab (ABBV-151)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Palazestrant in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palazestrant in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palazestrant in Metastatic Breast Cancer Drug Details: Palazestrant (OP-1250) is under...
-
Sector Analysis
NewUnited Kingdom (UK) Easter Market Analysis, Trends, Consumer Attitudes and Buying Dynamics, 2024 Update
United Kingdom (UK) Easter Market Report Overview The proportion of consumers agreeing that they did more Easter activities this year versus last year waned in 2024, as consumers opted for other activities during the long weekend. However, among those consumers with children, participation remained high, with over 62% of consumers with their youngest child being between 0-4 years of age agreeing that they did more Easter-related activities this year. As a result, retailers promoted various activities to encourage participation in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palazestrant in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palazestrant in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palazestrant in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Esophageal Cancer Drug Details: Cabozantinib s-malate (Cabometyx, Aptimetyx) is a...
-
Sector Analysis
NewUnited Kingdom (UK) Mother’s Day Market Analysis, Trends, Consumer Attitudes and Buying Dynamics, 2024 Update
United Kingdom (UK) Mother’s Day Market Report Overview The report suggests that over a third of male consumers agreed they spend more on taking their mother for a meal than buying a tangible gift. Indeed, if retailers cannot make gifting selections more appealing, consumers will turn to leisure over retail to mark the occasion. Therefore, retailers must promote experience gifts, which grew in popularity this year to compete with leisure options, such as dining out. The UK Mother’s Day market...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Diffuse Large B-Cell Lymphoma Drug Details: NKTR-255 is under development for the treatment...